Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1093 • ACR Convergence 2021
Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
Bindee Kuriya¹, Shadi Akhtari², Mohammad Movahedi³, Jacob Udell⁴, Patrick Lawler⁴, Paula Harvey⁵ and Lihi Eder⁴, ¹University of Toronto - Toronto, Toronto, ON, Canada, ²Women's College Hospital, University of Toronto, North York, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Inflammatory arthritis (IA) is associated with cardiovascular disease (CVD). Cardiac biomarkers may assist with CVD risk stratification. We aimed to estimate the prevalence, and…
Abstract Number: 1328 • ACR Convergence 2021
Assessment of Microvascular Involvement in Psoriatic Arthritis by Nailfold Capillaroscopy
Roba Ghossan¹, Nour Chouman², krystel aouad³, Mouin Jammal⁴, Rafic Baddoura¹, Ouidade Aitisha⁵, Jad Okais¹ and Fouad Fayad¹, ¹Rheumatology department, Saint-Joseph University, Beirut, Lebanon; Hotel-Dieu de France Hospital, Beirut, Lebanon, ²Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ³Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, ⁴Internal Medicine and Clinical Immunology department, Saint-Joseph University, Beirut, Lebanon; Hotel-Dieu de France Hospital, Beirut, Lebanon, ⁵Rheumatology department, Bellevue Medical Center, Mansourieh, Lebanon
Background/Purpose: Capillaroscopy has gained increasing importance in the microvascular assessment of rheumatic diseases (1). Increased cardiovascular risk has been observed in psoriatic arthritis (PsA) (2).…
Abstract Number: 1345 • ACR Convergence 2021
Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis: Results at 56 Weeks from the SELECT-PsA 1 Study
Iain McInnes¹, Koji Kato², Marina Magrey³, Joseph Merola⁴, Mitsumasa Kishimoto⁵, Cesar Pacheco Tena⁶, Derek Haaland⁷, Liang Chen⁸, Yuanyuan Duan⁹, Patrick Zueger¹⁰, Jianzhong Liu¹¹, Ralph Lippe¹², Aileen Pangan¹¹ and Frank Behrens¹³, ¹University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ²AbbVie Inc, Shinagawa- Ku, Japan, ³Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ⁶Facultad de Medicina, Universidad Autonoma de Chihuahua, Chihuahua, Mexico, ⁷McMaster University, Hamilton, Ontario and The Waterside Clinic, Oro Medonte, ON, Canada, ⁸AbbVie Inc., North Chicago, ⁹AbbVie Inc, North Chicago, ¹⁰AbbVie Inc., Mettawa, IL, ¹¹AbbVie Inc., North Chicago, IL, ¹²AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ¹³Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany
Background/Purpose: In the SELECT-PsA 1 study, through 24 weeks (wks), once daily upadacitinib 15 mg (UPA15) and 30 mg (UPA30) showed improvements in musculoskeletal symptoms,…
Abstract Number: 1361 • ACR Convergence 2021
Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patients with Active Psoriatic Arthritis and Ankylosing Spondylitis: Interim Analysis Results from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Nicola Gullick³, Gkikas Katsifis⁴, Anna Kandyli⁵, Jan Brandt-Jrgens⁶, Philippe Goupille⁷, Nicola Maiden⁸, Karl Gaffney⁹, Maher Aassi¹⁰, Barbara Schulz¹⁰, Effie Pournara¹⁰ and Piotr Jagiello¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ³University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, ⁴Rheumatology Clinic Naval Hospital of Athens, Athens, Greece, ⁵Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷University hospital of Tours, Rheumatology department, Tours, France, ⁸Craigavon Area Hospital, Southern Health & Social Care Trust, Portadown, Craigavon BT63 5QQ, Craigavon, United Kingdom, ⁹Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) has demonstrated long-lasting efficacy and a favorable safety profile in patients (pts) with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) across Phase…
Abstract Number: 1779 • ACR Convergence 2021
A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Nancy Shadick¹, Kumiko Schnock², Vivi Feather², Jing Cui³, Gabriela Maica², Alexa Marshall², Wynona Francis², Muibat Yussuff², Lourdes Maria Perez Chada², Michael E. Weinblatt² and Joseph Merola⁴, ¹Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…
Abstract Number: 1796 • ACR Convergence 2021
Early Identification of Psoriatic Arthritis with Axial Involvement Among Patients with Psoriasis: A Prospective Multicenter Study
Fabian Proft¹, Susanne Lüders², Theresa Hunter³, Gustavo Luna⁴, Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Katharina Meier⁵, Georgios Kokolakis⁵, Kamran Ghoreschi⁵ and Denis Poddubnyy⁶, ¹Charité University Medicine Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ³Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁴ICON plc, Stockholm, Sweden, ⁵Department of Dermatology, Venereology and Allergology – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: In the absence of reliable serological and/or imaging biomarkers for early psoriatic arthritis (PsA) and an existing diagnostic delay there is a need for…
Abstract Number: 1813 • ACR Convergence 2021
Clinical Characteristics & Outcomes Associate with Work Productivity in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study
Jeffrey Curtis¹, Iain McInnes², Proton Rahman³, Dafna Gladman⁴, Feifei Yang⁵, Steven Peterson⁶, Prasheen Agarwal⁷, Alexa Kollmeier⁸, Elizabeth Hsia⁹, Chenglong Han⁹, May Shawi¹⁰, William Tillett¹¹ and Philip Mease¹², ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, ⁷Department of Biostatics, Janssen Research & Development, LLC, Spring House, Spring House, PA, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC, Spring House, PA, ¹⁰Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ¹¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: PsA, a chronic inflammatory disease characterized by peripheral arthritis, axial inflammation, dactylitis, enthesitis and skin/nail psoriasis, causes impaired physical function, disability, and loss of…
Abstract Number: 1833 • ACR Convergence 2021
Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Muhammad Ajmal¹, Jawad Bilal¹, Syed Arsalan Ahmed Naqvi², Irbaz Bin Riaz³, Zaina Shahid⁴, Kaneez Zahra Rubab Khakwani¹, Yi-Shao Liu⁵, Sandipan Bhattacharjee⁵, Roxanne Bogucka⁵, Noureen Asghar⁶ and Kent Kwoh¹, ¹University of Arizona, Tucson, AZ, ²Dow University of Health Sciences, Karachi, Pakistan, ³Mayo Clinic, Phoenix, AZ, ⁴Lehigh Valley Health Network, Allentown, PA, ⁵University of Texas at Austin, Austin, TX, ⁶Dow University of Health Sciences, Karachi
Background/Purpose: The efficacy of biologics and targeted synthetic disease modifying antirheumatic agents approved for treatment of psoriatic arthritis (PsA) is well documented, but cardiovascular safety…
Abstract Number: 0053 • ACR Convergence 2021
Susceptibility Factors for Psoriatic Arthritis Single-cell RNA-Sequencing of Patients with Psoriatic Disease
Ameth Garrido¹, Rohan Machhar², Omar Cruz Correa³, Darshini Ganatra³, Sarah Crome⁴, Joan Wither³, Igor Jurisica⁵ and Dafna Gladman⁶, ¹Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Ajmera Transplant Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease that affects 30% of patients with psoriasis. Thus, early diagnosis of this subgroup is crucial to…
Abstract Number: 0232 • ACR Convergence 2021
The Impact of Deucravacitinib on Health-Related Quality of Life Measured by the Short Form Health Survey 36-Item Questionnaire: Analysis of a Phase 2 Trial in Patients with Active PsA
Vibeke Strand¹, Philip Mease², Atul Deodhar³, June Ye⁴, Miroslawa Nowak⁴, Jiyoon Choi⁴ and Brandon Becker⁴, ¹Stanford University School of Medicine, Portola Valley, CA, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ³Oregon Health & Science University, Portland, OR, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Patients (pts) with PsA experience pain, loss of physical function, joint damage, and significant impairments in social and emotional well-being. The Short Form Health…
Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Slawomir Jeka³, Javier De Toro Santos⁴, Eduardo Collantes-Estevez⁵, Fabricio Furlan⁶, Sohaib Hachaichi⁶ and Herbert Kellner⁷, ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Shropshire, United Kingdom, ²Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany, ³Clinic and Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Bydgoszcz, Poland, ⁴University Hospital Coruña, Servicio de Reumatología, A Coruña, Galicia, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁷Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…
Abstract Number: 1156 • ACR Convergence 2021
Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry
Jessica Walsh¹, Kelley Myers², Carol Mansfield², William Tillett³, Peter Nash⁴, Colton Leach², William Nowell⁵, Kelly Gavigan⁵, Patrick Zueger⁶, Erin McDearmon-Blondell⁷ and Alexis Ogdie-Beatty⁸, ¹Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ²RTI Health Solutions, Research Triangle Park, NC, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Griffith University, Brisbane, Australia, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶AbbVie Inc., Mettawa, IL, ⁷AbbVie Inc., Elmhurst, IL, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: To optimize patient-provider shared decision-making, it is important to understand patients’ experience with psoriatic arthritis (PsA) and its treatment, including how treatment experience may…
Abstract Number: 1329 • ACR Convergence 2021
Guselkumab (TREMFYA®) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study
Proton Rahman¹, Iain McInnes², Atul Deodhar³, Georg Schett⁴, Philip Mease⁵, May Shawi⁶, Daniel Cua⁷, Jonathan Sherlock⁸, Alexa Kollmeier⁹, Xie Xu⁷, Yusang Jiang⁷, Shihong Sheng⁷, Christopher Ritchlin¹⁰ and Dennis McGonagle¹¹, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁶Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Janssen Research & Development, LLC and University of Oxford, Spring House, PA, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: Guselkumab (GUS), a selective inhibitor of IL-23, significantly improved the diverse manifestations of active psoriatic arthritis (PsA), including dactylitis and enthesitis, in the DISCOVER…
Abstract Number: 1346 • ACR Convergence 2021
Comparable Safety Profile of Guselkumab in Psoriatic Arthritis and Psoriasis: Results from Phase 3 Trials Through 1 Year
Proton Rahman¹, Alice Gottlieb², Joseph Merola³, April Armstrong⁴, Richard Langley⁵, Mark Lebwohl², Christopher Griffiths⁶, May Shawi⁷, Ya-Wen Yang⁸, Elizabeth Hsia⁹, Alexa Kollmeier¹⁰, Xie Xu⁹, Miwa Izutsu¹¹, Paraneedharan Ramachandran¹¹, Shihong Sheng⁹, Yin You⁹, Megan Miller⁹, Christopher Ritchlin¹² and Iain McInnes¹³, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Keck School of Medicine, University of Southern California, Clinical Research, Los Angeles, CA, ⁵Dalhousie University, Division of Clinical Dermatology & Cutaneous Science, Halifax, NS, Canada, ⁶University of Manchester, Manchester Centre for Dermatology Research, Manchester, United Kingdom, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Global Services, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, Spring House, PA, ¹⁰Janssen Research & Development, LLC, La Jolla, CA, ¹¹Janssen Research & Development, LLC, Immunology, Spring House, PA, ¹²Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ¹³University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: DISCOVER 1&2 (PsA) and VOYAGE 1&2 (psoriasis [PsO]) are Phase 3 trials of guselkumab (GUS). Here we compared safety results through up to 1…
Abstract Number: 1362 • ACR Convergence 2021
No Change in Bone Marrow Edema of the Sacroiliac Joints and Spine After High Intensity Interval Training in PsA
Ruth Stoklund Thomsen¹, Tom Nilsen², Mari Hoff¹, Glenn Haugeberg³ and Arthur Kavanaugh⁴, ¹Dept. of Rheumatology, University Hospital of Trondheim, Norway ; Norwegian University of Science and Technology, Trondheim, Norway, Trondheim, Norway, ²Norwegian University of Science and Technology, Trondheim, Norway, Trondheim, Norway, ³Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway; Norwegian University of Science and Technology, Trondheim, Norway, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Physical activity is recommended for patients with psoriatic arthritis (PsA) especially due to the high prevalence of overweight/obesity, and the risk of comorbidities such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].